Actinium-225

Product description:

Actinium-225 (Ac-225) is emerging as one of the most promising radionuclides in Targeted Alpha Therapy (TAT). With its powerful alpha-emitting properties and suitability for radiopharmaceutical applications, Ac-225 has the potential to significantly enhance precision oncology and patient outcomes.
 

Why Actinium-225?

Alpha emitter with high energy
Enables effective destruction of cancer cells with minimal damage to surrounding tissues.
 
Favorable decay profile
10-day half-life ideal for radiolabeling and therapeutic applications.

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Powered by